Pinna Cellulitis Treatment
For pinna cellulitis, treat with oral anti-staphylococcal antibiotics covering both methicillin-sensitive Staphylococcus aureus (MSSA) and Pseudomonas aeruginosa, such as fluoroquinolones (ciprofloxacin) or combination therapy, as the pinna's cartilaginous structure and exposure make it susceptible to these organisms rather than the typical streptococcal pathogens of lower extremity cellulitis.
Key Distinction: Pinna vs. Typical Cellulitis
Pinna cellulitis differs fundamentally from typical lower extremity cellulitis. While the IDSA guidelines 1 and recent reviews 2, 3 emphasize that most non-purulent cellulitis is caused by β-hemolytic streptococci and MSSA, pinna cellulitis has a distinct microbiology due to:
- Cartilaginous involvement risk (perichondritis)
- Pseudomonas aeruginosa as a major pathogen
- Staphylococcus aureus (including MRSA in high-risk populations)
- Trauma or piercing history often present
Treatment Algorithm
First-Line Therapy
- Oral fluoroquinolone (ciprofloxacin 500-750 mg twice daily) provides dual coverage for both Pseudomonas and staphylococci
- Alternative: Combination of anti-staphylococcal agent (cephalexin, dicloxacillin) PLUS anti-pseudomonal coverage
Duration
- 5-7 days minimum for uncomplicated cases 3
- Extend if no improvement within 48-72 hours
When to Escalate
- Parenteral therapy if:
- Signs of perichondritis (cartilage involvement, fluctuance)
- Systemic toxicity present
- Failed oral therapy
- Immunocompromised patient
IV options: Piperacillin-tazobactam or ceftazidime plus vancomycin (if MRSA risk factors present)
Critical Pitfalls to Avoid
Do NOT treat pinna cellulitis like lower extremity cellulitis. The standard penicillin or cephalexin monotherapy recommended for typical cellulitis 2, 3 will miss Pseudomonas coverage and risks progression to perichondritis with permanent cartilage destruction.
MRSA Risk Factors to Consider
If present, add MRSA coverage 3:
- Athletes
- Recent incarceration
- IV drug users
- Prior MRSA infection
- Long-term care facility residents
- Men who have sex with men
Red Flags Requiring Immediate Escalation
- Perichondritis signs: Cartilage tenderness, fluctuance, deformity risk
- Systemic symptoms: Fever, chills (though these are more common with streptococcal infections 4)
- Rapid progression despite appropriate antibiotics
- Immunosuppression
Evidence Limitations
The provided guidelines 1 focus on typical lower extremity cellulitis where streptococci predominate. The evidence shows oral antibiotics are non-inferior to IV therapy for uncomplicated cellulitis 5, and macrolides outperform penicillins 6. However, none of these studies specifically address pinna cellulitis, which requires extrapolation based on anatomic site-specific microbiology and risk of cartilage involvement.
The IDSA guidelines 1 acknowledge that pathogen identification occurs in <20% of cellulitis cases, making empiric coverage essential. For pinna cellulitis specifically, the cartilaginous anatomy and Pseudomonas risk mandate broader initial coverage than typical cellulitis.